Fiche publication
Date publication
janvier 2021
Journal
Critical reviews in biomedical engineering
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GANGI Afshin
,
Dr GARNON Julien
,
Pr BAYLE Bernard
Tous les auteurs :
Garnon J, Meylheuc L, Jennings J, Koch G, Cazzato R, Bayle B, Gangi A
Lien Pubmed
Résumé
Polymethylmethacrylate (PMMA) bone cement is increasingly being used for percutaneous minimally invasive treatments of patients suffering from bone malignancies. PMMA is composed of a polymeric powder and a monomeric liquid. Once mixed, the polymerization process begins and leads to a viscous fluid that can be injected through a bone trocar. Cement progressively hardens within the bone, leading to a viscoelastic solid material. PMMA interacts with the surrounding cancellous bone through mechanical interlocking via interdigitations in trabecular bone. It can also bond with hardware, such as titanium screws, as it penetrates the macro- and micro-irregularities of the hardware. PMMA itself has no antineoplastic effects but may be used as a stand-alone treatment to provide pain palliation and bone consolidation through mechanical reinforcement, notably in areas with high compression load. It can also be used to reinforce the anchorage of screws in case of a landing zone with poor bone quality due to underlying malignant osteolysis.
Référence
Crit Rev Biomed Eng. 2021 ;49(1):35-50
